Specify a stock or a cryptocurrency in the search bar to get a summary
Scandion Oncology A/S
SCOLScandion Oncology A/S, a clinical-stage biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase II clinical trial for the treatment of colorectal cancer; and in Phase I clinical trial for treating pancreatic cancer, as well as in preclinical studies for other cancer indications. The company is also developing SCO-201, which is in preclinical trial for the treatment of solid tumors/HIV. The company was incorporated in 2017 and is headquartered in Copenhagen, Denmark. Address: Symbion, Copenhagen, Denmark, 2100
Analytics
WallStreet Target Price
10.07 SEKP/E ratio
1.0071Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures SCOL
Dividend Analytics SCOL
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History SCOL
Stock Valuation SCOL
Financials SCOL
Results | 2019 | Dynamics |